Background: Delay in diagnosis of breast cancer can occur at several points on the diagnostic pathway. We examined characteristics of women with breast cancer who before diagnosis actively refused recommended follow-up of tests or symptoms suggestive of breast cancer. Methods: We identifi ed women aged 50 years or older diagnosed with latestage (metastatic disease or tumors ≥ 3cm at diagnosis) and a matched sample of women with early-stage (tumors < 3 cm) breast cancer from 1995 to 1999. Using medical records, we investigated clinical characteristics, use of health care, and documentation of care refusal during the 3 years before diagnosis. We used logistic regression models to compare refusers to nonrefusers. Results: Of the 2694 women studied, 7.2% refused provider follow-up advice during the 3 years. 
patient characteristics associated with this delay. Delay during this period can be categorized into three main types: patient delay, provider delay, and delay due to system factors ( 11 ) . Of these, patient delay appears to be a major contributor to untimely follow-up in some populations ( 12 -14 ) , and explicit patient refusal to consent to timely follow-up is one cause of patient delay ( 13 , 15 , 16 ) .
Patient characteristics reportedly associated with delayed follow-up of a positive mammogram or CBE include low estimated household income ( 17 ) , poor health status ( 12 , 18 ) , no history of previous screening mammograms ( 17 ) , few mammograms in the 5 years before diagnosis ( 12 ) , absence of a palpable lump and atypical symptoms at initial medical consultation (19 , 20 ) , patient underestimation of the importance of following up a positive test ( 18 ) , travel or holiday plans ( 18 ) , patient too busy ( 18 ) , patient fearful ( 18 ) , and transportation problems ( 12 ) . However, little is known about patient characteristics associated with explicit refusal of follow-up.
In a case -control study investigating reasons for late-stage breast cancer in seven health maintenance organizations, our research team found that women with medical record -documented evidence of patient noncompliance with or refusal of breast care before breast cancer diagnosis had higher odds of late-stage disease than women who did not refuse care ( 23 ) . We conducted a secondary analysis in this population to obtain more information on women who refused one or more recommendations for follow-up of tests or symptoms suggestive of breast cancer during the 3 years before breast cancer diagnosis. We examined the characteristics of these women who refused important aspects of patient care, despite having obtained comprehensive prepaid healthcare coverage. We also investigated the reasons the women gave for their actions and the settings in which the refusals occurred.
M ETHODS Setting
This study was conducted within the Cancer Research Network (CRN), a consortium of research organizations affi liated with nonprofi t integrated healthcare delivery systems and the National Cancer Institute. The CRN consists of the research programs, enrollee populations, and databases of 11 Hawaii, Henry Ford Health System, and Group Health Cooperative) participated in a study to evaluate the reasons for late-stage breast cancer in prepaid health plans. These health plans provide comprehensive primary care, including cancer screening, diagnosis and treatment, to about 1.5 million women aged 50 years and older. Details of the study design and methods are described elsewhere ( 23 ) . The study was approved by the institutional review boards of all seven health plans; all IRBs waived informed consent for this data-only study.
Study Subjects
In brief, the study included 1347 late-stage breast cancer cases (women with metastatic cancer or tumors ≥ 3 cm.) diagnosed between 1995 and 1999 inclusive in women aged 50 years and older and 1347 control subjects with early-stage breast cancer individually matched to cases on health plan, age within 1 year, and diagnosis within 6 months. Women with a prior history of breast cancer were excluded, but women with a history of breast procedures (such as implants, reductions, and biopsies) were not excluded.
Data Sources and Measures
The study collected data from medical records, cancer registries, health plan membership databases, pharmacy databases, and U.S. Census records. Data items collected included demographic variables (age, ethnicity, race, marital status, and census block group), data on the breast cancer (date of diagnosis, tumor characteristics), and information on all breast-related medical visits in the 3 years up to diagnosis (breast cancer screening services provided, any breast cancer symptoms reported, examination fi ndings, and follow-up recommendations).
The medical record abstraction collected information on refusal of breast care during two periods prior to breast cancer diagnosis. For each woman reporting breast-related symptoms during a clinical encounter or those with an abnormal mammogram or CBE during the 3-year study period, medical record abstractors obtained information about follow-up of the symptoms/ abnormal result. Abstractors would choose the option " patient refused provider advice " if clinical notes documented that the woman explicitly refused recommended follow-up cancer care at the time of the recommendation. They recorded the patient's stated reason for refusing recommended services as documented by the provider in the medical record and copied the page from the medical record, so that the study analyst could confi rm the abstractor's interpretation of refusal and further analyze the exact wording of the notation. The word " refusal " did not have to specifi cally occur in the clinical notes, but it had to be clear to the abstractor and the analyst that the patient did refuse recommended diagnostic tests at the time they were offered. We did not attempt to validate this information on refusal by contacting the patient or family. The three settings at which refusal during the study period could occur included 1) a clinical visit, 2) the mammography appointment, and 3) a follow-up telephone encounter. In addition to refusal information collected in the 3-year period before diagnosis, notes made in the chart during the 3-year study period might indicate that the patient was noncompliant or refused breast care prior to the study, and abstractors recorded this prior refusal in a separate variable.
In this analysis, we used the term " refusers " to describe women whose medical records documented at least one refusal of provider recommendations for follow-up of abnormal screening results or breast cancer symptoms during the study period. The term " nonrefusers " is used to describe the study subjects with no chart notation of refusal of follow-up during this period. We did not consider any of the following to be refusal of followup: refusal of screening before a suspicious fi nding was noted, delayed initial visit for obvious signs or symptoms, request for a second opinion, request for a temporary delay where diagnosis occurred within 3 months of the request, or refusal of one diagnostic procedure but acceptance of another (e.g., refusal of additional mammographic views but agreement to ultrasound); these subjects are classifi ed as nonrefusers.
We used education and income information obtained from the 2000 U.S. Census for census tract of residence as surrogates for subject education and family income. We calculated the proportion of refusers and nonrefusers living in a census tract where less than 25% of women had a college education (median for nonrefusers). We also calculated the proportions of refusers and nonrefusers with geocoded family income less than $40 000 per year, $40 000 to $54 999 per year, $55 000 to $71 999 per year, and $72 000 per year or more (quartiles for nonrefusers).
Statistical Analyses
We used descriptive analysis to evaluate the demographic and clinical characteristics of refusers, overall and by stage (late versus early). We enumerated the reasons documented in the medical record for refusal and described the medical settings where refusal occurred. We also calculated the length of time between fi rst refusal of follow-up in the study period and diagnosis date. Since the convention for selecting the diagnosis date varied slightly from one health plan to another, we maintained consistency in our analysis across health plans by using the date of the pathology procedure at which cancer was confi rmed.
We compared refusers with nonrefusers on demographic and clinical factors. We fi t unconditional logistic-regression models, adjusting for health plan, stage, and other covariates to calculate odds ratios for the refuser -nonrefuser comparisons. We initially stratifi ed the analysis on stage (late/early), since stage was the basis for the original study's control group selection ( 23 ) . Results within each stage were similar, so only the combined results are presented.
R ESULTS
Of the 2694 women in the study population, 195 (7.2%) refused provider advice on follow-up at least once during the 3-year observation period according to medical record documentation. This proportion varied by health plan with a range of 4.9% -10.3%. More refusers (64%) had late-stage breast cancer at diagnosis than did nonrefusers (49%) (odds ratio [OR] = 1.9, 95% confi dence interval [CI] = 1.4 to 2.5). Since late-stage cases represented 50% of the study population but only 17.6% of the incident invasive breast cancers in these health plans during 1995 -1999 (based on reporting from four sites), the overall proportion of refusers of follow-up among subsequently diagnosed breast cancer cases in the seven health plans during this period was estimated to be 6.0%.
Refusers were more likely than nonrefusers to be elderly (35% aged 75 or older compared with 22% of the nonrefusers) (OR = 1.9, 95% CI = 1.4 to 2.7 for age 75 or older compared with ages 50 -64) ( Table 1 ) . Refusers and nonrefusers did not differ materially by race, menopause status, family history of breast cancer, or number of years of health plan enrollment. Refusers were more likely than nonrefusers to have six or more children (OR = 2.3, 95% CI = 1.3 to 4.2 for six or more children compared with one to two children).
We observed no association between refusal status and median family income of the census tract of residence or between refusal status and living in a census tract with less than 25% of women with a college education. These variables did not alter the results of any of the other demographic or clinical variables.
Medical record documentation of refusal or noncompliance before the study period was more common for refusers during the study period (17%) than nonrefusers during the study period (5%) (OR = 3.9, 95% CI = 2.5 to 6.2) ( Table 2 ). Among refusers, * Logistic regression models adjusted for site, age group, and stage. CI = confi dence interval; -= odds ratios not calculated for subjects classifi ed as "unknown".
† Quartiles based on distribution among nonrefusers. 82 (42%) fi rst refused care in the study period between 1 and 3 years before breast cancer diagnosis, whereas 113 (58%) refused care in the year before breast cancer diagnosis but not during the 2 years previously. We calculated a median of 363 days from fi rst refusal of follow-up in the study period to the date of the pathology procedure at which cancer was confi rmed. For 25% of refusers, fewer than 32 days passed between fi rst refusal and pathology confi rmation. Another 25% of refusers had more than 746 days (slightly more than 2 years) between refusal and pathology confi rmation. More than half the refusers (61%) had breast cancer symptoms noted in the medical chart in the 3 years before breast cancer diagnosis; a slightly lower proportion of nonrefusers (58%) had symptoms before diagnosis ( Table 2 ). The two groups did not differ materially in the distribution of breast cancer symptoms reported (i.e., lump, pain, nipple discharge, visual change, odor). Fewer refusers (19%) than nonrefusers (31%) were diagnosed using screening mammography; refusers were more likely than nonrefusers to be diagnosed using CBE.
The refusers used the medical care system; almost all women had at least one outpatient visit in the study period, and all but one had at least one CBE in the study period ( Table 2 ) . Refusers were less likely to have mammography in the study period than nonref users (OR = 0.34, 95% CI = 0.22 to 0.54), but they were more likely to have fi ve or more CBEs (OR = 2.5, 95% CI = 1.7 to 3.8), compared to 1 or 2 CBEs. Refusers were more likely than nonrefusers to have missed one or more appointments (OR = 2.0, 95% CI = 1.4 to 2.9).
For the women who refused care in the study period, we reviewed the reasons for refusal noted in the medical record ( Table 3 ) . Although in most cases (68%) no reason was recorded, the most frequently documented reasons for refusal included avoidance -denial -fatalism (11%), fear of further diagnostic tests (4%), fear of surgery and/or disfi gurement (3%), and discomfortpain of mammogram (3%).
Most documented refusals occurred at a clinical encounter ( Table 3 ). The primary medical services refused by the women involved immediate clinical evaluation and included biopsy, immediate mammogram, and surgical referral. Only two of the 14 women who refused care at a mammography visit also refused care at a clinic visit. Of the 34 subjects who refused care at a telephone contact, 16 (47%) had also refused care at a clinic visit, whereas 18 (53%) had no documentation of previous refusal of care at a clinic visit or mammography department visit. The main procedures refused at a telephone contact involved immediate clinical evaluation (surgical referral and immediate mammogram).
D ISCUSSION
This report describes a group of women who had prepaid healthcare coverage but actively refused recommended diagnostic tests for breast cancer. Most had frequent contact with the medical system during the 3-year period before breast cancer 2) more than 3 y before diagnosis * Logistic regression models adjusted for site, age group, and stage. OR = odds ratio, CI = confi dence interval; -= odds ratios not calculated for subjects classifi ed as "unknown" .
† During period 3 years before diagnosis of breast cancer. diagnosis, and most had received at least one mammogram and CBE during this period. Most of these women were later diagnosed with late-stage breast cancer. Among demographic factors, advanced age and high parity were most strongly associated with refusal of follow-up care in our study. Concerns about poor general health status may have infl uenced the decisions of the elderly women; for two, advanced age was mentioned as the reason for refusal. Otherwise, refusal reasons mentioned by elderly women and women with high parity were similar to reasons given by other refusers.
Among clinical and medical-care factors, refusers were more likely than nonrefusers to have a history of refusal of care before the study period. Refusers were also about twice as likely as nonrefusers to have a history of missed medical appointments. Refusers were less likely than nonrefusers to have screening mammograms in the study period or to be diagnosed using mammography. Several women cited the discomfort and pain of mammograms as the reason for refusing follow-up mammography and for refusing mammograms prior to the study period. Dislike or fear of mammography also may have been the reason that refusers were more likely than nonrefusers to have more CBEs in the study period; women may have requested CBE as an alternative procedure. Two previous studies conducted in prepaid health plans also found a defi cit of mammography among women with delayed follow-up of a positive mammogram ( 12 , 17 ) .
In our study, the reasons for refusal were not well documented in the health plan medical records. Records contained no information on the reason for refusal for more than two-thirds of refusers. Avoidance and denial were reported for about 11%. Fear of diagnostic tests and surgery and fear of disfi gurement were also expressed by some. Few subjects in these prepaid health plans claimed that fi nancial or family concerns prevented follow-up.
Future efforts encouraging providers to accurately record reasons for refusal of follow-up would be valuable for later intervention and to better understand this behavior.
To our knowledge, few other studies have ascertained patient reasons for refusal of or noncompliance with diagnostic testing for breast cancer. In a study of elderly African American women attending a public clinic for treatment of chronic illnesses ( 13 ) , 27% of the women with abnormal mammograms refused diagnostic follow-up. Reported reasons for refusal included nonspecifi c " fears " and the belief that they were too old for treatment Other reasons cited by these women included the desire to " not want to know if something is wrong " and the perception that " nothing was bothering them. " A study investigating patient reports of processes of care related to breast cancer screening follow-up ( 24 ) in four prepaid health plans found high adherence with recommendation for immediate evaluation but lower compliance with request for additional imaging or 4-to 6-month follow-up. Overall, for 7% of subjects with abnormal mammograms, one or more recommended tests were not done. Subjects reported that lack of adherence was partially due to confusing and confl icting information provided by medical personnel.
Limitations of our study include using medical records to ascertain the reasons for refusal, which resulted in incomplete documentation and could have been affected by documentation bias, since we collected provider notation of the reasons for refusal, not the women's self-report. Providers' perceptions of these reasons may not have been accurate, and providers may have selectively recorded some reasons but not others. We did not have information on the level of education or family income of study subjects and instead used estimates derived from the U.S. Census block groups. Despite these limitations, the large study size and the ethnically and geographically diverse population were major study strengths. Other study strengths included excellent access to medical records to ascertain patterns of health care. Almost all selected subjects were included in the analysis. The study collected detailed information on breast-related clinical encounters and mammography visits and specifi cally attempted to collect as much information as possible on patient refusal of care.
In conclusion, we found patient refusal of follow-up in a proportion of this population of health plan members with breast cancer. Patient characteristics associated with refusal of followup included advanced age, high parity, low use of mammography, high use of CBE, and missed appointments. Although all study subjects were eventually diagnosed with breast cancer, our data suggest that refusal of follow-up is associated with delay in diagnosis and treatment of same. Further study is needed on the characteristics of women who refuse follow-up tests for breast cancer and the impact of such refusal on outcomes. Also, efforts aimed at identifying and counseling women with abnormal results who refuse follow-up are warranted.
